Company intelligence / Profile preview

BioGend Therapeutics

Ownership: Private
Development stage: Commercial

Overview

BioGend Therapeutics develops and commercializes orthopedic medical devices focused on synthetic bone graft substitutes and autologous cartilage repair. Its lead products include BiG‑001 for long bone applications, BiG‑006 for lumbar interbody fusion, and BiG‑009 for autologous cartilage repair. The company has demonstrated significant revenue growth in recent years as its products advance through clinical development and commercialization in Taiwan and select international markets.

Therapeutic areas: OtherRheumatology
Modalities: Synthetic bone graft substitutesbiological aggregates (bone and cartilage repair systems)
Industry: Implantable Medical Devices

Drug pipeline

3 assets

RevoCart

Commercial

Indications: Knee cartilage repair

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on BioGend Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioGend Therapeutics.

Explore the full profile